DE602004013427T2 - Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen - Google Patents

Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen Download PDF

Info

Publication number
DE602004013427T2
DE602004013427T2 DE602004013427T DE602004013427T DE602004013427T2 DE 602004013427 T2 DE602004013427 T2 DE 602004013427T2 DE 602004013427 T DE602004013427 T DE 602004013427T DE 602004013427 T DE602004013427 T DE 602004013427T DE 602004013427 T2 DE602004013427 T2 DE 602004013427T2
Authority
DE
Germany
Prior art keywords
compound
alkyl
compound according
aryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004013427T
Other languages
German (de)
English (en)
Other versions
DE602004013427D1 (de
Inventor
Thavalakulamgara K. Edison SASIKUMAR
Wen-Lian Edison WU
Duane A. Bernardsville BURNETT
Li Edison QIANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of DE602004013427D1 publication Critical patent/DE602004013427D1/de
Application granted granted Critical
Publication of DE602004013427T2 publication Critical patent/DE602004013427T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE602004013427T 2003-02-28 2004-02-26 Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen Expired - Lifetime DE602004013427T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45079903P 2003-02-28 2003-02-28
US450799P 2003-02-28
PCT/US2004/005780 WO2004078745A1 (en) 2003-02-28 2004-02-26 Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders

Publications (2)

Publication Number Publication Date
DE602004013427D1 DE602004013427D1 (de) 2008-06-12
DE602004013427T2 true DE602004013427T2 (de) 2009-06-04

Family

ID=32962533

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004013427T Expired - Lifetime DE602004013427T2 (de) 2003-02-28 2004-02-26 Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen

Country Status (12)

Country Link
US (1) US7498441B2 (enExample)
EP (1) EP1601664B1 (enExample)
JP (1) JP4570165B2 (enExample)
CN (1) CN1777596A (enExample)
AR (1) AR043420A1 (enExample)
AT (1) ATE393766T1 (enExample)
CA (1) CA2517088A1 (enExample)
DE (1) DE602004013427T2 (enExample)
ES (1) ES2305735T3 (enExample)
MX (1) MXPA05009193A (enExample)
TW (1) TW200427679A (enExample)
WO (1) WO2004078745A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2121613A2 (en) 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors
WO2010011756A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
CA2732765A1 (en) 2008-08-06 2010-02-11 Vertex Pharmaceuticals Incorporated Aminopyridine kinase inhibitors
EP2427464A1 (en) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
EP2582702A1 (en) 2010-01-27 2013-04-24 Vertex Pharmaceuticals Incorporated Pyrazolopyrimidine kinase inhibitors
MX2012008641A (es) 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopirazinas.
WO2011094273A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
KR20180095564A (ko) * 2015-12-22 2018-08-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤조피페리딘 유도체, 이의 제조 방법 및 이의 의학적 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
HUP0002713A3 (en) * 1997-05-30 2001-02-28 Neurosearch As 8-azabicyclo[3,2,1]oct-2-ene and octane derivatives, process for preparation thereof, pharmaceutical compositions comprising thereof and their use
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2002006245A1 (en) 2000-07-05 2002-01-24 Synaptic Pharmarceutical Corporation Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof
ATE460163T1 (de) * 2001-04-12 2010-03-15 Pharmacopeia Llc Arly und diaryl piperidinderivate verwendbar als mch-hemmer
MXPA05000185A (es) * 2002-06-27 2005-04-08 Schering Corp Piperidinas espirosustituidas como antagonistas selectivos del receptor de la hormona concentrada de mealnina para el tratamiento de la obesidad.

Also Published As

Publication number Publication date
AR043420A1 (es) 2005-07-27
TW200427679A (en) 2004-12-16
WO2004078745A1 (en) 2004-09-16
EP1601664A1 (en) 2005-12-07
US20040176355A1 (en) 2004-09-09
DE602004013427D1 (de) 2008-06-12
EP1601664B1 (en) 2008-04-30
CA2517088A1 (en) 2004-09-16
JP4570165B2 (ja) 2010-10-27
US7498441B2 (en) 2009-03-03
MXPA05009193A (es) 2005-10-18
ATE393766T1 (de) 2008-05-15
JP2006520399A (ja) 2006-09-07
ES2305735T3 (es) 2008-11-01
CN1777596A (zh) 2006-05-24

Similar Documents

Publication Publication Date Title
DE60204548T2 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
EP1448526B1 (en) Piperidine-based mch antagonists for treatment of obesity and cns disorders
DE69103206T2 (de) Neue Derivate des Aminopiperidins, Aminopyrrolidins und des Aminoperhydroazepins, Verfahren zur Herstellung und diese enthaltende Arzneimittel.
US6667319B2 (en) Neuropeptide Y Y5 receptor antagonists
DE60319714T2 (de) Agonisten des cannabinoidrezeptors
DE60213629T2 (de) Piperidinverbindungen als muscarinantagonisten
DE60307289T2 (de) Spirosubstituierte piperidine als selektive antagonisten des melanin konzentrierenden hormon rezeptors für die behandlung von fettleibigkeit
DE69919171T2 (de) Muskarin-rezeptor antagonisten
US20040034008A1 (en) New neuropeptide Y Y5 receptor antagonists
KR20050044664A (ko) 비만 치료용 ｍｃｈ 길항제로서의ｎ-아릴-ｎ'-아릴사이클로알킬-우레아 유도체
DE602004013427T2 (de) Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
WO2005021528A1 (en) 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
DE60025348T2 (de) Ethansulfonyl-piperidin-derivate
JP2006520399A5 (enExample)
JP4605801B2 (ja) 肥満治療用のｍｃｈアンタゴニスト
JP2007521286A5 (enExample)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition